Pfizer Bets on Gene Therapy with Spark Therapeutics Deal

Source: Spark Therapeutics

Dec 09, 2014

Pfizer has struck a deal worth potentially $280M with privately-owned U.S. biotech Spark Therapeutics to develop treatments for Hemophilia B.

Additionally, Pfizer has announced that it will be establishing a gene therapy platform to study potential treatments, led by Michael Linden, a professor from King’s College London and director of the University College London Gene Therapy Consortium -- the latest sign from drugmakers that gene therapy might be ready for prime time.

According to Spark, the biotech will receive an upfront payment of $20 million and will be eligible for additional development and commercialization milestone payments of up to $260 million for multiple hemophilia B product candidates that may be developed underthe collaboration. Spark will be responsible for conducting all Phase 1/2 studies while Pfizer will assume responsibility for pivotal studies, any regulatory approvals and potential global commercialization of the product.

 Read the Spark press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments